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Abstract. Anatomy and physiology of the eye makes it a highly protected organ. Designing an effective
therapy for ocular diseases, especially for the posterior segment, has been considered as a formidable
task. Limitations of topical and intravitreal route of administration have challenged scientists to find
alternative mode of administration like periocular routes. Transporter targeted drug delivery has
generated a great deal of interest in the field because of its potential to overcome many barriers
associated with current therapy. Application of nanotechnology has been very promising in the treatment
of a gamut of diseases. In this review, we have briefly discussed several ocular drug delivery systems such
as microemulsions, nanosuspensions, nanoparticles, liposomes, niosomes, dendrimers, implants, and
hydrogels. Potential for ocular gene therapy has also been described in this article. In near future, a great
deal of attention will be paid to develop non-invasive sustained drug release for both anterior and
posterior segment eye disorders. A better understanding of nature of ocular diseases, barriers and factors
affecting in vivo performance, would greatly drive the development of new delivery systems. Current
momentum in the invention of new drug delivery systems hold a promise towards much improved
therapies for the treatment of vision threatening disorders.
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INTRODUCTION
Ocular drug delivery has remained as one of the most
challenging task for pharmaceutical scientists. The unique
structure of the eye restricts the entry of drug molecules at
the required site of action. Drug delivery to the eye can be
broadly classified into anterior and posterior segments
(Fig. 1). Conventional systems like eye drops, suspensions
and ointments cannot be considered optimal in the treatment
of vision threatening ocular diseases (1). However, more than
90% of the marketed ophthalmic formulations are in the form
of eye drops. These formulations mainly target the anterior
segment eye diseases (2). Most of the topically applied drugs
are washed off from the eye by various mechanisms
(lacrimation, tear dilution and tear turnover) resulting in
low ocular bioavailability of drugs. Moreover, human cornea
comprising of epithelium, substantia propria and endothelium
also restricts the ocular entry of drug molecules (3). As a
result of these factors less than 5% of administered drug
enters the eye. Alternative approaches like incorporation of
permeation enhancers/cyclodextrins and increasing the vis-
cosity of solutions did not provide any significant improve-
ment. Recently many drug efflux pumps have been identified
and significant enhancement in ocular drug absorption was
achieved following their inhibition or evasion. But prolonged
use of such inhibitors may result in undesirable effects (4).
Treatment of posterior segment diseases still remains a
herculean task for the formulation scientists. The tight
junctions of blood retinal barrier (BRB) restrict the entry of
systemically administered drugs into the retina (5). High
vitreal drug concentrations are required in the treatment of
posterior segment diseases. This can be made possible only
with the local administration (intravitreal injections/implants
and periocular injections). Periocular injections are associated
with fairly high patient compliance as compared to intra-
vitreal injections (6).
Dramatic changes have been observed in the field of
ocular drug delivery over a decade. Insight into various
membrane transporters/receptors present on the eye opened
a new window of opportunities. Especially polar drug
molecules, which fail to permeate ocular barriers, can be
conveniently delivered via transporter/receptor targeted drug
delivery systems (7). This review article briefly covers
pathology of various ocular diseases and their current
therapies. We have also given emphasis on the role of various
ocular transporters and recent developments in drug delivery
strategies including gene therapy. We have briefly discussed
ocular deliver systems, gene therapy, and recent develop-
ments like microneedle and iontophoresis
OVERVIEW ON ANATOMYAND DISEASES
AFFECTING EYE
Broadly we discuss the structure of eye under two
subheadings (a) anterior segment and (b) posterior segment.
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Anterior segment consists of front one-third of eye that
mainly includes pupil, cornea, iris, ciliary body, aqueous
humor, and lens while the posterior segment consists of the
back two-thirds of the eye that includes vitreous humor,
retina, choroid, macula, and optic nerve (Fig. 1) (8, 9). In this
article we made an attempt to briefly discuss the major
diseases affecting the eye. These include age-related macular
degeneration (AMD), diabetic macular edema (DME),
cataract, proliferative vitreoretinopathy (PVR), uveitis, cyto-
megalovirus (CMV), and glaucoma. Table I highlights the
classification, signs and symptoms and current treatment
options for these diseases.
DELIVERY ROUTES
Conventionally, many ocular diseases are treated with
either topical or systemic medications. Topical application of
drug has remained the most preferred method due to ease of
administration and low cost. Topical application is useful in
the treatment of disorders affecting the anterior segment of
the eye (10). Anatomical and physiological barriers hinder
drugs from reaching posterior segment of eye mainly at
choroid and retina. A major fraction of drug following topical
administration is lost by lacrimation, tear dilution, nasolacri-
mal drainage and tear turnover. Such precorneal losses result
in very low ocular bioavailability. Typically, less than 5% of
the total administered dose reaches aqueous humor (11). So,
in order to maintain minimum inhibitory concentrations, the
agents need to be frequently dosed resulting in poor patient
compliance. Upon topical instillation drugs are absorbed
either by corneal route (cornea → aqueous humor →
intraocular tissues) or non-corneal route (conjunctiva →
sclera → choroid/RPE). The preferred route depends mainly
on the corneal permeability of drug molecules (12). Unlike
topical administration, systemic dosing helps in the treatment
of diseases affecting posterior segment of the eye. A major
drawback associated with systemic administration is only 1–
2% of administered drug reaches to vitreous cavity. Blood
retinal barrier which is selectively permeable to more
lipophilic molecules mainly governs the entry of drug
molecules into posterior segment of the eye. This results in
frequent administration of high amounts of drugs leading to
systemic side effects (13). Though topical and systemic routes
are convenient, lack of adequate bioavailability and failure to
deliver therapeutic amounts of drugs to the retina prompted
the vision scientists to search for alternative routes of
administration.
Intravitreal injections have gained considerable momen-
tum during the past two decades. This method involves
injection of drug solution directly into vitreous via pars plana
using a 30 G needle. Unlike other routes, intravitreal
injection offers higher drug concentrations in vitreous and
retina. Elimination of drugs following intravitreal administra-
tion depends on their molecular weight. Linear and globular
shaped molecules (especially protein and peptide drugs) with
molecular weight greater than 40 and 70 kDa respectively
tend to cause longer retention in vitreous humor (14).
Though intravitreal administration offers high concentra-
tions of drugs in retina, it is associated with various short term
complications such as retinal detachment, endophthalmitis and
intravitreal hemorrhages (15). Moreover, patients need to be
carefully monitored following intravitreal injections.
Periocular route has been considered as the most
promising and efficient route for administering drugs to
posterior eye segment. Periocular refers to the region
surrounding the eye. It is a broad term which includes
peribulbar, posterior juxtascleral, retrobulbar, subtenon and
subconjunctival routes (Fig. 2). Drug solutions are placed in
close proximity to the sclera which results in high retinal and
vitreal concentrations. Sclera which is made up of fibrous
tissue offers less resistance to permeability of drugs (16).
Ghate et al., studied the pharmacokinetics of sodium fluores-
cein following periocular administration in rabbits. The study
concluded that administration of drug via subtenon injection
resulted in the highest and sustained vitreous concentration of
sodium fluorescein compared to retrobulbar and subconjunc-
tival routes (17). Anterior segment complications have been
observed in some patients following periocular injections.
These include rise in intraocular pressure, cataract, hyphema,
strabismus and corneal decompensation (18).
NUTRIENT TRANSPORTERS AND EFFLUX PUMPS
IN THE EYE
Epithelial cells express various nutrient transporters and
receptors on their membrane surface. These nutrient trans-
porters aid in the movement of various vitamins and amino
acids across the cell membrane. Our laboratory has exten-
sively studied various transporters and receptors which are
present on ocular structures. We have also shown that
attachment of various transporters/receptors targeted ligands
enhances ocular bioavailability significantly. A detailed dis-
cussion of all influx transporters is beyond the scope of this
review. So, we have mentioned some the important ones.
PEPTIDE TRANSPORTER
It is a fairly robust transporter which has gained
considerable attention in recent years for targeted drug
delivery (19). These proton coupled transporters help in the
translocation of di and tripeptides across the epithelium (20).
These proteins are mainly classified into PepT1, PepT2 and
peptide/histidine transporters (PHT 1 and PHT 2). Many
drug molecules are known to be substrates for these trans-
porters. Our laboratory has shown the presence of an
oligopeptide transporter on rabbit cornea (21). Other drugs
including β-lactam antibiotics, renin inhibitors and ACE-
inhibitors are known to be substrates for PepT1 and PepT2.Fig. 1. Structure of eye.
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Ocheltree et al., demonstrated the expression of PHT1 in
BRPE, HRPE (human RPE cells), ARPE-19 (human RPE
cell line), and bovine and human neural retina. However,
they could find the expression PEPT2 and PHT2 only in
bovine and human retina; and PEPT1was not detected. They
also concluded that glycylsarcosine uptake studies did not
demonstrate any significant functional activity of PHT1 on
plasma membranes of RPE (22). We have also investigated
the mechanism of model dipeptide (glycylsarcosine) transport
across the blood-ocular barriers following systemic adminis-
tration in our laboratory. A time and concentration depen-
dent, carrier mediated uptake of glycylsarcosine across the
blood-ocular barrier was reported (23). Prodrugs (valine-
ACVand valine-valine-ACV) exhibited higher concentrations
of ACV in aqueous humor following systemic administration
as compared to parent drug. This study indicates that peptide
prodrugs are taken up via carrier mediated transport mecha-
nism (24). Hence, drugs with poor ocular bioavailability can
be suitably modified so that they can be recognized by
peptide transporters.
GLUCOSE TRANSPORTER
Glucose is utilized by the retina to meet the energy need
of oxidative metabolism. Neural retina is considered to have
the highest metabolic rate per unit weight (25). So, an
alteration in the metabolic rate can lead to potential ocular
complications. Glucose is transported across the blood-retinal
and blood aqueous barriers by a stereo-specific, saturable
process of facilitated diffusion. Glucose transporters are
expressed in various isoforms GLUT1, GLUT2, GLUT3,
GLUT4, GLUT5, GLUT6 and GLUT7. Out of these GLU1,
GLU3, and GLU4 are high-affinity glucose transporters
where as GLUT5 is a high-affinity fructose transporter.
GLUT2 is considered to be low affinity glucose transporter.
GLUT6 is a pseudogene which does not encode for a
functional transporter. GLUT7 is similar to GLUT2 but only
expressed in endoplasmic reticulum (26). Mantych et al.,
studied the presence of various isoforms of glucose transport-
er (Glut 1, Glut 3, Glut 4, and Glut 5) in human eye using
western blot and immunohistochemical techniques. This
study reported presence of Glut 1 in RPE, choroid, pars
plana, retinal Mueller cells, and lens fiber cells (27). Glucose
transporters are more efficient and have more capacity than
any other nutrient transporter. But high substrate specificity
of glucose transporters renders them inefficient for drug
delivery purpose.
VITAMIN C TRANSPORTER
Vitamin C or ascorbic acid (AA) acts as an antioxidant
and thereby protects the cornea and other ocular tissues from
UV radiations. Aqueous humor is the main source of AA for
cornea and lens. AA levels in aqueous humor are partly
responsible for preventing cataract (28). Two specific trans-
porters (SVCT-1 and SVCT-2) of vitamin C were identified in
the ocular tissues of human, rabbit and rat. These trans-
porters have identical sequence homology. Transport of AA
across the cells is mediated by two different transporter
families. One consists of the low affinity and high capacity
facilitative hexose transporters (GLUT) which translocate
dehydro ascorbic acid (oxidized form of ascorbic acid), and
the other consists of high affinity and low capacity sodium
dependent vitamin C transporters (SVCT1 and SVCT2) that
ferries L-ascorbic acid (reduced form of ascorbic acid) (29).
AMINO ACID TRANSPORTER
Amino acids are responsible for protein synthesis and
maintenance of structural and functional integrity of conjunc-
tiva and retina/RPE. These transporters help in transferring
amino acids from circulating blood to various organs. The
presence of various amino acid transporters (ASCT1, LAT1
and ATB0+) on the cornea has been confirmed by gene
expression. These transporters are actively involved in the
transportation of L-alanine, L arginine and L-phenylalanine
across the cornea. Amino acid transporters can be classified
on the basis of their sodium dependency and substrate
specificity (30). System L (large) and system y+ (cationic)
amino acid transporters belong to sodium independent
transporters while system X- (anionic), system A, B0,+, ASC
(anionic, cationic, and neutral amino acid transporters) belong
to sodium dependent transporter category (21). Large neutral
amino acid transporter is expressed in two isoforms LAT1 and
LAT2. LAT1 is mainly involved in the transport of large
neutral amino acids, such as Leu, Phe, Ile, Trp, Val, Tyr, His
and Met while LAT2 transports both large neutral amino acids
and small neutral amino acids (31, 32). Transport systems for
amino acids have been characterized on corneal epithelium
and endothelium. Gandhi et al., studied the biochemical
evidence of sodium independent facilitative transport system,
LAT2, with high substrate specificity on ARPE-19 cell line
(33). Blisse et al., reported the presence of sodium-dependent,
B0,+ amino acid transporter with broad substrate specificity on
rabbit corneal epithelium and human cornea. This transporter
belongs to neurotransmitter gene family and found to have
affinity comparable to PEPT1 in the transport of prodrugs,
like valine-ACV and valine-GCV (34, 35). Such transport
systems may be efficiently targeted for enhancing ocular
delivery of drugs.
EFFLUX TRANSPORTERS
Efflux of various substrates across plasma membrane and
cytoplasm into extracellular fluid is mainly governed by ABC
Fig. 2. Routes of ocular drug delivery.
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(ATP-binding cassette) superfamily of proteins which are
encoded by MDR1 gene (36). ABC transporters are broadly
classified into two types (a) complete transporter, contains
four units (two nucleotide-binding domains and two mem-
brane bound domains) and (b) half transporter, which
possesses only two units (one nucleotide-binding domain
and one membrane-bound domain). Half transporter must
attach with another half transporter to perform its action (37).
These ABC proteins are actively involved in detoxification
process by regulating the transport of various sterols, lipids,
endogenous metabolic products and xenobiotics (38). Litera-
ture search reveals that mainly two multidrug efflux pumps
are responsible for the development of chemoresistance (a)
P-glycoprotein (ABCB1) and (b) multidrug resistant protein
(MRP) (ABCC1) (39).
P-gp is a 170 kDa membrane bound efflux protein
generally expressed on the apical surface of polarized cells
(40). P-glycoprotein is actively involved in the efflux of drug
molecules thereby reducing drug accumulation inside cells
(41). The presence of P-gp in the eye has been confirmed on
conjunctival epithelial cells (42), ciliary non-pigmented epi-
thelium (43), human and rabbit cornea (44), retinal capillary
endothelial cells, iris and ciliary muscle cells (45). Constable
et al., studied the presence of P-gp on three human RPE cell
lines, ARPE19, D407 and h1RPE. They concluded that only
D407 cell functionally express P-gp and hence can be used for
in vitro drug transport studies without any modifications (46).
MRP is a 190 kDa membrane bound efflux protein
encoded by MRP1 gene. It is generally expressed on the
basolateral surface of intestine, hepatocytes and kidney cells
(47, 48). Till now 12 different members of MRP family have
been studied (49). MRP's are actively involved in the
effluxing glucuronide, sulfate conjugated compounds and
organic anions. Aukunuru et al., studied the presence of
functionally and biochemically active MRP on human RPE
cell line (50). Further studies by Steuer et al., confirmed that
MRP is present on the choroidal side of the outer blood
retinal barrier (51). Recently, studies from our laboratory
revealed the presence of ABCC2 (a MRP homologue) on
human corneal epithelium and rabbit cornea (52). Recently
Zhang et al., have performed an extensive research on
implications of drug transporter and CYP P450 mRNA
Expression in ocular drug disposition. They concluded that
both BCRP and MRP2 have very low expression levels in the
human cornea while there were moderate MRP1 and low
MRP3 expression levels in the human cornea. Moreover,
designing drugs that can efficiently evade MRP1 efflux may
play an important role in enhancement of ocular penetration
(53).
Efflux pumps constitute significant barriers to the entry of
drug molecules. It is indeed necessary to develop alternative
strategies which can improve ocular drug absorption.
PRODRUG APPROACH TO ENHANCE OCULAR
BIOAVAILABILITY
Prodrug strategy has been attempted for improving
therapeutic efficacy of many drug molecules. Significant
advantages in various properties like solubility, stability,
permeability and evasion of efflux pump have been gained.
Shirasaki has recently reviewed various molecular approaches
to enhance drug permeation across the cornea (54). Our
laboratory has also aggressively pursued the exploitation of
many of these transporters for ocular drug absorption. Amino
acid and peptide prodrugs of acyclovir (ACV) and ganciclovir
(GCV), targeting various amino acid and peptide transporters
have been developed and evaluated in our laboratory.
Dipeptide (glycine–valine and tyrosine–valine) monoester
prodrugs of GCV were found to show superior corneal
absorption and bioavailability compared to parent drug (55).
These attempts are highly effective in treating herpes simplex
virus-1 (HSV-1) induced corneal epithelial and stromal
keratitis (56). Permeability values of valine–GCV, tyrosine–
valine–GCV, and glycine–valine–GCV were found to be
higher than parent GCV which was attributed to their
interaction with oligopeptide transporter present on the
retina (57). Sustained release microsphere formulations of
GCV and its lipophilic prodrug GCV–monobutyrate, with
higher entrapment efficiency, were developed using PLGA in
our laboratory (58). By using a similar strategy, L-valyl ester
of acyclovir (ACV) was also developed and found to be more
permeable across rabbit cornea due to its interaction with the
oligopeptide transporter (24). Ocular penetration of peptide
prodrug of ACV (valine–valine–ACV), was higher than the
parent drug following systemic administration in rabbits. The
prodrugs appear to be less cytotoxic, highly water-soluble
with excellent in vivo activity against HSV-1 in rabbit
epithelial and stromal keratitis (59). Our laboratory has also
demonstrated that prodrug derivatization can effectively
circumvent P-gp mediated efflux of quinidine across rabbit
cornea (60).
TG100801, which converts to TG100572 by de-esterification,
was found to be effective in the treatment of ocular neo-
vascularization and retinal edema following topical adminis-
tration (61). Due to this prodrug approach, incidence of
systemic toxicity was found to be greatly diminished. Role of
phase I and phase II ocular metabolic activities was also
reviewed recently to rationalize design of prodrug and co-
drug for ocular delivery by Crooks et al., (62). UNIL088, a
water-soluble prodrug of cyclosporine A was developed via
an ester linkage which gets converted into parent drug by
chemical or enzymatic hydrolysis of the terminal ester group
(63). Cannabinoids usually lowers IOP by their interaction
with the ocular cannabinoid receptors. The solubility related
problem of cannabinoids was solved by making arachidony-
lethanolamide, R-methanandamide, noladin ether and their
water-soluble phosphate ester prodrugs (64). This modifica-
tion has resulted in higher corneal permeation which could
result in more efficient reduction in IOP. In another study,
combretastatin A-4-phosphate (CA-4-P), a water soluble
prodrug of combretastatin A-4 (CA-4), was found to suppress
the development of VEGF-induced neovascularization in the
retina and also block development of CNV (65). Topical
formulation of nepafenac was found to effectively penetrate
into the corneal tissue which also reaches into the posterior
segment. In animal models it was found to inhibit CNV and
ischemia-induced retinal neovascularization. Nepafenac is
converted to amfenac which has significant higher perme-
ability across the cornea. This property is primarily respon-
sible for appearance of the nepafenac to the posterior
segment and causing inhibition of VEGF (66).
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NOVEL OCULAR DRUG DELIVERY SYSTEMS
Colloidal carriers have been widely exploited in the field
of drug delivery science. It provides a more selective targeting
along with sustained release of molecules at the desired site.
Applications of nanotechnology can be very exciting in the
treatment of a gamut of diseases affecting the anterior as well
as the posterior segment of the eye. One has to understand
the physiological and biochemical factors involved in normal
and pathological conditions for designing a successful ocular
drug delivery system.
An ideal therapy requires selectively targeting of active
agent to various diseases like CNV, diabetic retinopathy and
solid tumors in the eye. Retina does not possess lymphatic
system moreover angiogenesis in this part of eye has similar
features to the solid tumor with enhanced permeability and
retention (EPR) effects (67, 251). Delivery of a drug via
nanotechnology based product fulfills mainly three objectives
as follows (1) enhances drug permeation (2) controls the
release of drug (3) targets drug (251). Main focus was given to
colloidal systems consisting of micro/nanoparticles, micro/
nanoemulsions, nanosuspensions and liposomes. In the last
decade, dendrimers, niosomes, and cyclodextrins have also
been exploited to achieve optimal drug delivery. Ocular
implants have also been emerged as an alternative to the
conventional delivery systems. The role of iontophoresis and
ultrasound has also gained momentum in ocular delivery.
Encapsulation of drugs in these colloidal carriers can also
significantly enhance permeation across the membrane and
prevent degradation from the ocular enzymes (68, 69). Such
biodegradable carriers can be developed as an alternative to
the implant prepared from nonbiodegradable polymers,
which has to be removed surgically after a certain period.
Sometimes the surgical process can cause complications like
astigmatism, vitreous hemorrhage and patient incompliance.
MICROEMULSIONS
Microemulsions are dispersions of water and oil facili-
tated by a combination of surfactant and co-surfactant in a
manner to reduce interfacial tension. These systems are
usually characterized by higher thermodynamic stability,
small droplet size (∼100 nm) and clear appearance (70). A
review on application of microemulsions in ocular drug
delivery by Vandamme et al., deals systematically with the
various developments and challenges happening in the field.
Selection of aqueous phase, organic phase and surfactant/co-
surfactant systems are critical parameters which can affect
stability of the system. Optimization of these components
results in significant improvement in solubility of the drug
molecule e.g. indomethacin, chloramphenicol (71). Apart
from solubility, microemulsion systems have also been
exploited to improve permeation across the cornea. An oil-
in-water system consisting of pilocarpine using lecithin,
propylene glycol, PEG 200 as surfactant/co surfactants, and
isopropyl myristate as the oil phase has been designed, which
is nonirritating to the rabbit animal model (72). Such
formulations often provide sustained drug release thereby
reducing frequency of the drug administration. In case of
pilocarpine, microemulsion based system lowers the frequen-
cy of administration to two times as compared to four times
with conventional eye drops in a day. This was due to
enhancement of the permeation by surfactant-co-surfactant
combination. Another microemulsion system consisting of
pilocarpine hydrochloride (73) was shown to convert in
different forms like (liquid crystalline and coarse emulsion)
with a change in rheological parameters which changed
depending upon change in water content. This results in
higher viscosity which will retain the formulation on the
cornea resulting in its enhanced effect. Timolol in micro-
emulsion system was laden in a 2-hydroxyethyl methacrylate
(HEMA) gels which was studied to modulate its transport
across the gel (74). The authors have achieved higher drug
loading but could not control its release. In another attempt
to deliver timolol, a stable o/w and w/o emulsion was
formulated which met all the requirements of an eye drop
according to Polish Pharmacopeia V. Sirolimus, a highly
lipophilic drug with aqueous solubility of 2.6 μg/mL was
formulated in microemulsion system which could hold 1 mg of
drug in the system with excellent stability and tolerability
(75). An alcohol free, microemulsion based formulation
consisting chloramphenicol was developed. This formulation
exhibited excellent stability when compared to commercially
available formulation. Though microemulsions have excellent
advantages limitations in selection of surfactant/co-surfactant
system and potential toxicity associated with higher concen-
trations of surfactant/co-surfactant often restricts its use (76).
NANOSUSPENSIONS
This can be defined as sub-micron colloidal system which
consists of poorly water-soluble drug, suspended in an
appropriate dispersion medium stabilized by surfactants.
Nanosuspenisons usually consist of colloidal carriers like
polymeric resins which are inert in nature. They help in
enhancement of drug solubility and thus bioavailability.
Unlike microemulsions, they are also popular because of
their non irritant nature. Flurbiprofen encapsulated in
eudragit RS 100® and RL 100® polymer resins prevents
myosis, which might be induced during extracapsular cataract
surgery (77). Charge on the surface of nanoparticles facili-
tates its adhesion to the cornea. Methylprednisolone acetate
(MPA) was encapsulated in a copolymer of poly (ethyl-
acrylate, methyl-methacrylate and chlorotrimethyl-ammo-
nioethyl methacrylate) and examined for its effect on the
anti-inflammatory symptoms in rabbits with endotoxin-in-
duced uveitis (EIU) (78). Animal studies have revealed that
anti-inflammatory effect of nanosuspensions was more than
microsuspensions. Similar studies were carried out using
piroxicam in eudragit RS 100. In vivo studies in rabbits have
shown significant anti-inflammatory effects compared to
microsuspensions (79). In another approach, three different
types of glucocorticoids; hydrocortisone, prednisolone and
dexamethasone were formulated as nanosuspensions. In vivo
study in rabbits suggested that the nanosuspensions signifi-
cantly enhanced the ocular absorption of glucocorticoids (80).
These nanosuspensions also produce sustained drug release
and were more effective over a longer duration. Nano-
suspensions also impart stability to the drug in the formulation.
Cloricromene (AD6) was formulated in nanosuspensions by
using eudragit RS100 and RL100. AD6-loaded eudragit
retarded nanoparticle suspension offered a significant edge in
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enhancing the shelf life and bioavailability of the drug
following ophthalmic application (81).
NANOPARTICLES
According to Sahoo et al., “Nanoparticles are defined as
particles with a diameter of less than 1 μm, comprising of
various biodegradable or non biodegradable polymers, lipids,
phospholipids or metals” (251). They can be classified as
nanospheres or nanocapsules depending upon whether the
drug has been uniformly dispersed or coated within polymeric
material. Recent studies have revealed the migration of intact
nanoparticles to the RPE cells following intravitreal injection
of nanoparticles suspension (82, 251). This migration had been
attributed to the rupture of the internal limiting membrane
(ILM) and activation of non-specific retinal microglial cells.
Such mild transient mechanism in the inflammatory process
also modifies permeability and the anchoring mechanism of
the ILM. These findings are crucial for the diseases affecting
the posterior segment of the eye. Uptake and distribution of
nanoparticles depend on the size of the nanoparticles. Kinetics
of fluorescein nanospheres (2000, 200 and 50 nm) was studied
following intravitreal injection in rabbits. Nanospheres smaller
than 200 nm were also observed in the retinal cells other than
the vitreous cavity and trabecular meshwork where only larger
diameter particles were distributed. This study has shown the
importance of particle size in ocular tissue distribution (83).
Many formulation parameters have to be considered in
designing an ideal formulation. Surface charge interaction of
the drug and polymer has played an important role in drug
release from the polymer. Incomplete release of progesterone
from the polybutyl cyanoacrylate nanospheres was attributed
to the surface charge interaction of the drug and polymer (84,
251). A solid lipid nanoparticulate system of tobramycin was
developed for topical drug delivery. Such a particulate system
can be retained for longer duration on the corneal surface and
also on the conjunctival sac compared to an aqueous solution
of the drug. In vivo testing has shown sustained drug release
over a period of 6 h compared to short duration from equal
dose of eye drops (85). Recently Kompella et al., have
evaluated how the ocular disposition and distribution of
different size of nanoparticles (20 and 200 nm) vary due to
blood and lymph circulations following periocular administra-
tion in Sprague Dawley rats (86). They found that particles
with 20 nm size were transported across the sclera to a small
extent and no significant transport was noted across the
sclera-choroid-RPE. Such low permeation was attributed to
periocular circulation (blood and lymphatic) which play a
crucial role in clearing the 20 nm particles. A higher
concentration of particles in the ocular tissues was observed
in dead animals by the post-mortem studies which they
concluded because of the lack of physiological barrier follow-
ing periocular administration. An ideal nanoparticulate formu-
lation should have low clearance by blood and lymphatic
circulation in order for it to be effective in the treatment of
posterior segment diseases following periocular administration.
Various naturally occurring polymers were studied as
carriers for the nanoparticulate system. Albumin nanopar-
ticles can effectively encapsulate both positively (GCV) and
negatively charged (oligonucleotides (ODNs)) molecules
(87). Chitosan coated poly (epsilon-caprolactone) nanopar-
ticles of indomethacin resulted in twofold enhancement in
ocular bioavailability (88). Enhanced permeation across the
cornea was also observed when poly (epsilon-caprolactone)
nanoparticles were coated with polyethylene glycol (89). In
another study, a formulation comprising dexamethasone
acetate encapsulated in biodegradable PLGA nanoparticles
was administered by the intravitreal route and the effect on
CNV was studied. This study demonstrated a triphasic
pattern of drug release. The drug level was found to be more
than the level required to treat CMV (90). In another study,
mucoadhesive chitosan-sodium alginate nanoparticles were
prepared and evaluated for topical delivery of gatifloxacin.
This system resulted in burst release during the first hour
followed by sustained release for 24 h. This approach helps in
reducing the dosing frequency of the antibiotic because of the
sustained action observed after single administration (91).
Moshfeghi et al., have extensively reviewed the perspec-
tives of particulate delivery system (micro and nanoparticles)
in ophthalmology (92). Intravitreal administration of red
nuclear fluorescent protein entrapped in PLGA has been
shown to localize in RPE cells where red nuclear fluorescent
protein plasmid expression was also observed (93). Phosphor-
othioate ODNs were either adsorbed or incorporated in
albumin nanoparticles and antiviral efficacy was examined.
Nanoparticles having entrapped ODNs were found to exhibit
higher antiviral activity than nanoparticles with the adsorbed
drug on the surface. This may be due to the protection of
ODNs from enzymatic degradation (94). Particulate delivery
system of ODNs has resulted in their higher stability, efficacy
and reduction in non specific toxicity (95, 96). Currently, we
are working on the delivery of various steroidal nanoparticles
of mean particle diameter ≈200 nm via subconjunctival
administration. In our laboratory, we are also working to
optimize various in vitro properties of steroidal nanoparticles.
These nanoparticles can be suspended in thermosensitive gels
for subconjunctival administration. Further attachment of
various ligands (folate and biotin) to the surface of these
nanoparticles helps in increasing the uptake by RPE cells. This
approach can be applied for the treatment of various posterior
segment diseases such as wet AMD, PVR and DME.
Microspheres can sustain the release of the ODNs after
intravitreal injection for longer time period. Asmicrospheres do
not enter the cells, a new approach called “Trojan” delivery
system was invented. In this type of delivery system, polymeric
microspheres were designed to control release of the nanosized
anti-TGFβ2 phosphorothioate ODNs complexes. Such “Tro-
jan” delivery was much more efficient for bleb survival
following trabeculectomy than the microsphere or control alone
(97). Macugen® was also entrapped in microspheres and
studied following transscleral delivery. In vitro release study
has shown release of macugen (2 μg/day) up to 20 days across
the sclera. Inhibition of endothelial cell proliferation confirmed
that biological activity was not affected by encapsulation (98).
LIPOSOMES
Liposomes are lipid vesicles containing aqueous core
which have been widely exploited in ocular delivery for
various drug molecules. Liposomes containing GCV were
formulated by a reversed phase evaporation method and in
vivo pharmacokinetic evaluation was performed in a rabbit
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model. Permeability of GCV solution was compared with the
liposomal formulation containing GCV. Transcorneal perme-
ability and area under the curve (AUC) were was 3.9 and 1.7
fold higher than the solution. Ocular tissue distribution was
higher in the sclera, cornea and vitreous humor from
liposomal formulation (99). Vasoactive intestinal peptide
(VIP) was formulated in liposomal formulation (VIP-Lip).
Concentration of VIP following intravitreal injection was
about 15 times higher in ocular fluid than the concentration
achieved by administration of VIP solution alone. The
peptide was effective only when formulated in liposomal
form (100). Ciprofloxacin (CPFX) was also formulated in
liposomal environmental which lowered tear-driven dilution
in the conjunctival sac. Multilamellar vesicles from lecithin
and alpha-L-dipalmithoyl-phosphatidylcholine were used to
prepare liposome containing CPFX. This approach produced
sustained release of the drug depending on the nature of the
lipid composition selected (101). Acetazolamide was encap-
sulated in liposomal formulation for delivery via topical route.
Liposomes were prepared using reversed-phase evaporation
(REVs) and multilamellar vesicles (MLVs). Different molar
ratios of phosphatidylcholine and cholesterol were added in
the preparation of MLVs which resulted in higher entrapment
efficiency as compare to REV. Entrapment efficiency
ascended with higher amounts of lipid and charge inducers
such as cholesterol and stearylamine. In-vivo intraocular
pressure was examined for selective formulation and lip-
osomes. MLVs exhibited prolong efficacy than liposomes
prepared by REV (102). In another study cationic liposomes
containing herpes simplex virus type 1 (HSV-1) glycoprotein
B (gB1s) or, DTK1 and DTK2 (two related polylysine rich
peptides) were prepared and examined in the rabbit ocular
model of HSV-1 keratitis. These peptides (antigen) in
liposomal formulation have the potential to act as very
effective anti-HSV vaccine (103). In a similar manner,
liposomes of tilisolol were also prepared and studied follow-
ing topical and intravitreal administrations. Positively charged
liposomal formulation of tropicamide and oligolamellar lip-
osomes of ACV were generated. Both formulations resulted
in significantly higher absorption across the cornea (104).
Antisense ODNs encapsulated in liposomes have been
studied for their potential to treat ocular disorders. Various
factors need to be carefully considered before such a system
is adopted clinically. In topical delivery, liposome may not be
able to release the entire payload of high molecular weight
ODNs relative to a free solution form (105). Liposomal
formulation can release ODNs in a sustained manner
following intravitreal injection (106). PEGylated liposome
containing ODNs, results in higher percentage of intact
ODNs (30% of the total dose) after 2 weeks. Some
researchers have formulated liposomes coated with an
envelope of inactivated hemagglutinating virus of Japan
(HVJ) to treat CNV in rats. They successfully delivered
phosphorothioate ODNs to inhibit VEGF (107).
NIOSOMES
Niosomes are bilayered structural vesicles made up of
non-ionic surfactant which are capable of encapsulating both
lipophilic and hydrophilic compounds. In a recent approach
to deliver cyclopentolate, niosomal formulation was devel-
oped. It released the drug independent of pH resulting in
significant enhancement of ocular bioavailability (108, 251).
Niosomal formulation of coated (chitosan or carbopol) timolol
maleate exhibited significant IOP lowering effect in rabbits as
compared to timolol solution. Another novel delivery system
known as discomes has been developed. These are large
structures with a size range of 12–16 μm derived by incorpo-
rating nonionic surfactant Solutan C24 in niosomes. A major
advantage of this system was less systemic drainage because of
the large size and large residence time in the cul-de-sac due to
their disc shape. Timolol maleate was successfully entrapped in
discomes and niosomes. In vivo bioavailability of the discomes
was better than the niosomes (109, 251).
DENDRIMERS
According to Sahoo et al., “Dendrimers are macro-
molecular compounds made up of a series of branches around
a central core. Their nanosize, ease of preparation, function-
alization and possibility to attach multiple surface groups
render them suitable alternative vehicle for ophthalmic drug
delivery” (110, 111, 251). Previously, poly (acrylic) acids were
prepared as bioadhesive polymers to achieve better residence
time and decrease the frequency of administration. Major
drawbacks associated with these systems are blurred vision and
formation of a veil leading to vision loss (112). Dendrimers are
liquid or semi-solid polymers and contain amine, carboxylic
and hydroxyl surface groups, which keep on increasing as the
generation number increases (G0, G1, G2, and so on).
Dendrimers consisting of poly (amidoamine) (PAMAM) have
been widely employed in drug delivery. This system of
branched polymers represent unique architecture, and can
entrap both hydrophilic and lipophilic drugs into their structure
(113–115, 251). Selection of functional group on the surface
(amine, carboxylate and hydroxyl), size and molecular weight
of the dendrimer are important parameters to be considered in
designing a delivery system.
Dendrimer based approach has shown better bioavailabil-
ity of pilocarpine and tropicamide, when DG1.5 and DG4.0
(OH) dendrimers with carboxylate and hydroxyl surface
groups were instilled (116). Some of the researchers have
synthesized water soluble conjugates of D(+)-glucosamine and
D(+)-glucosamine 6-sulfate to obtain synergistic immuno-
modulatory and antiangiogenic effect by using anionic
PANAM (G3.5) dendrimers (117). The investigators have also
shown successful increase in long term surgery after testing the
formulation in a rabbit model of scar tissue formation after
glaucoma filtration surgery. Cell-adhesion peptides were also
attached to dendrimers which were later used to link with
collagen scaffolds (118). Stratification of corneal epithelial cell
was studied using the above mentioned collagen scaffolds. All
peptides have shown promoted effect on stratification. The
same investigators have actively developed biocompatible
conjugates of dendrimers with collagen scaffolds to obtain
better mechanical property and adhesion ability. In another
approach, dendrimers based approach was used to deliver anti-
VEGF ODN and successfully tested in rats to treat CNV (119).
Effect of size, molecular weight and number of surface groups
(amine, carboxylate and hydroxyl) of PANAM was studied to
understand feasibility for its controlled release of pilocarpine
nitrate and some tropicamide (116).
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CYCLODEXTRINS
As per Sahoo et al., “Cyclodextrins (CDs) belong to a
group of cyclic oligosaccharides capable of forming inclusion
complexes with many guest molecules (120). Through CD
complexation, aqueous solubility of hydrophobic drugs can be
enhanced without changing their molecular structure and
their intrinsic ability to permeate biological membranes
(251)”. Molecules having low aqueous solubility have been
delivered as CD complexes. These complexes have been
proven to increase corneal permeation of drugs like dexa-
methasone, cyclosporine and so on. CD complexation
approach can significantly increase ocular bioavailability of
poorly water soluble drugs. In some cases such inclusion
complexes can impart aqueous stability to drugs within the
formulation as well (121). Recently a study was carried out to
determine relative concentration of dexamethasone in CDs
following topical and systemic absorption in the rabbit eye.
Investigators observed a significant amount of drug reaching
to the posterior segment tissue like retina and vitreous humor
following topical application of eye drops. Such an approach
might be very valuable in the treatment of vitreoretinal
diseases which require long term delivery of drug molecules
(122). In another study, the researchers have prepared inclu-
sion complex of HP-β-CD with zinc diethyldithiocarbamate
and disulfiram which resulted in higher corneal permeability
and also lower side effects like development of cataract
relative to drug alone (123, 124). In a similar approach,
inclusion complexes were prepared with rhEGF/HP-β-CD
which were suspended in poloxamer gel. This formulation has
resulted in significant increase in AUC of the drug. This
approach has an additional advantage of imparting stability to
the drug (125). Inclusion complexes of drugs like dexameth-
asone, dexamethasone acetate and pilocarpine with HP-β-CD
resulted in higher bioavailability than the conventional eye
drops (126, 127). This complexation approach does not
disrupt the biological membrane compared to conventional
permeation enhancer like benzalkonium chloride. Apart from
that, due to inclusion, the free drug is not available, so drugs
with inherent irritant properties can be successfully delivered
by this approach. CD molecules are inert in nature and HP-β-
CD (up to 45%) was found to be non irritant to the human
and animal eye (120).
CONTACT LENSES
Liewen et al., reported an extensive study on polymeric
hydrogels for contact lens-based ocular drug delivery (128).
Traditionally used soaked contact lenses provide a drug
release for a few hours. Current challenges in this mode of
drug delivery are to sustain release for longer period and also
to incorporate sufficient drug amounts in the lens matrix.
Recently, surfactant loaded (Brij 98) poly-hydroxy ethyl
methacrylate (p-HEMA) gel has shown sustained release of
cyclosporine-A (129). In a similar approach, dexamethasone,
dexamethasone 21-disodium phosphate and dexamethasone
21-acetate were suspended in p-HEMA based gel to achieve
controlled release (130). The bioavailability of the formula-
tion was found to be better than the topical eye drops. In a
different kind of approach, two different kind of silicone and
hydrogel lens were compared for 1 month. The silicon based
lens was shown to be more beneficial to the patient with
hypoxia but also found to form more lipid deposit compared
to the other. The same investigators have prepared silicon
based hydrogel using different ratios to sustain the release of
the timolol, dexamethasone, and dexamethasone 21-acetate
over the time of several weeks to 3 months (131). The
different ratios of monomers could be changed depending
upon the delivery required. The prepared lenses were also
studied for its mechanical and physical properties. The
residence time of a system could be lengthened by suspending
nanoparticulate based drugs in thermogelling polymers. The
contact lens, containing a nanoparticulate based drug, is an
attractive alternative to the topical drug delivery, especially
eye drops (3, 132). A major benefit of this strategy is to
prolong residence time in post tear film which in case of
topical drops is just a few minutes. Due to increased residence
time in eye, drug permeation through the cornea is higher
with specific delivery of the drug to targeted tissue. In
another study, drug molecule entrapped in a nanoparticulate
system was later dispersed in lens made up of poly-2-
hydroxyethyl methacrylate (p-HEMA) hydrogels. This ap-
proach provide controlled drug release over a few days and
delivery rate could be further modulated by changing loading
dose of the particles in the gel (133).
INTRAOCULAR IMPLANTS
Implants have been widely employed to extend the
release in ocular fluids and tissues particularly in the posterior
segment. Implants can be broadly classified into two catego-
ries based on their degradation property (1) biodegradable
and (2) non-biodegradable. With implants, the delivery rate
could be modulated by varying polymer composition.
Implants can be in the form of solid, semi-solid or particulate
based delivery systems (134). These implants have been
applied in the treatment of diseases affecting both anterior
and posterior segments of the eye. The diseases include
anterior segment disorders like glaucoma filtering surgery
and posterior segment disorders like proliferative vitroretin-
opathy, CMV retinitis, endophthalmitis, and posterior capsule
opacification. Table II summarizes the recent strategies of
formulating an implant for various ocular pathologies.
Drug release from Poly lactic acid (PLA), poly glycolic
acid (PGA) and poly lactic-co-glycolic acid (PLGA) usually
follows three phases of drug release which constitute an initial
burst, a middle diffusive phase and a final burst of the drug.
In recent years, much attention has been paid to manipulate
release profiles to achieve longer duration of release from the
implants (135, 136). In one study, two PLA monomers of
different molecular weight were used in different ratios and, a
pseudo-zero order release was obtained with minimum burst
effect (137). Recently, co-polymerization of caprolactone with
poly-glycolide-co-lactide lead to the development of glyco-
lide-co-lactide-co-caprolactone copolymer (PGLC) which was
successfully applied to treat corneal allograft and uveitis (138,
139). Polyanhydrides have also been utilized for these
indications (140). Polyorthoesters (POE) are hydrophobic in
nature and usually degrade by surface erosion thus providing
zero order release kinetics. Among the four generations, third
generation POE forms gel like matrix at room temperature.
Fourth generation POEs have gained much attention cur-
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rently because of their slow erosion property due to the
presence of latent acid in the polymer backbone (141).
Recently, researchers have also focused on intravitreal
injection of implant using cell encapsulation technology. FGF-
2 implant embedded in AN69 copolymer delayed photore-
ceptor degeneration (142). Various synthetic polymers like
polyether sulfone, caprolactone and polyvinylpyrrolidone
were developed and then positioned with a titanium anchor
in the vitreous cavity (143). In a similar study, ciliary
neurotrophic factor (CNTF) was released from cells
implanted without any side effects for several weeks. A dose
dependent protective effect on photoreceptors was noticed
with CNTF in rabbits (144). A novel device ECT NT-501 was
developed to support the implanted cells (145). After loading
CNTF secreting cells in the device, a controlled release of
protein was observed for 1 year in the rabbit eye. In a clinical
trial, this device appeared to protect photoreceptors in
several patients (146).
HYDROGEL SYSTEMS
These are three-dimensional, hydrophilic, polymeric net-
works capable of imbibing large amounts of water or biological
fluids. Nanjawade et al., have extensively reviewed hydrogels
in ocular delivery (147). Residence time can be significantly
enhanced with a hydrogel formulation. The gelation can be
obtained by changing temperature and pH. Poloxamers, the
most widely used polymer, contain the hydrophobic part in the
centre surrounded by a hydrophilic part. Though they are
widely employed to enhance the residence time, they suffer
from a major drawback of having weak mechanical strength,
rapid erosion and non-biodegradability (148). Many attempts
have been made to address this problem. Oligomerization was
carried out to change the critical gelling temperature. In case
of cellulose derivative like HPMC, gelation is a result of
interaction of hydrophobic components at higher temperature
(149). Pilocarpine formulation has shown enhanced miotic
response at lower concentration of xyloglucan than poloxamer
407 (150). Pseudolatexes are artificial latexes obtained by
dispersing pre-existing polymers in aqueous medium. They
offer physical stability of gel along with the drug molecule
which are sensitive to aqueous media (151).
In a different sort of gel approach also known as
ATRIGEL, a polymer is dissolved in a suitable carrier. The
polymer and carrier are both biodegradable and biocompat-
ible. Once injected into the subcutaneous space, water in
surrounding tissue causes the precipitation of polymer which
immediately entraps the drug and releases it in a controlled
manner (www.qltinc.com). The inventors of the product have
claimed to use this system for a wide variety of molecules i.e.
proteins and peptides. Targeted delivery of drugs, compati-
bility with a wide variety of molecules, potential to achieve
controlled release and biocompatibility were the key features
of the system (www.qltinc.com). Currently marketed product,
Table II. Implants for the Treatment of Ocular Pathologies
Drug Polymer Characteristic/treatment Ref
Episcleral implant of betamethasone PVA- EVA Zero order release up to 4 weeks (204)
Triamcinolone acetonide (TA) PVA Controls CNV in a rat model (205)
Dexamethasone scleral implant (Surodex®) PLGA After phacotrabeculectomy surgery (206)
Intracameral implant of cyclosporine PLGA Prevents corneal graft rejection or
post-operative inflammation in rats
(207)
5-Fluorouracil (5-FU) POE Less toxicity and persistence bleb
for longer time
(208)
Combination of drug 5-fluorouridine, TA and
recombinant tissue plasminogen activator
PLGA Treatment of PVR after intravitreal
injection
(209)
Cis-4-hydroxyproline PLGA 65/35 + PLGA 50/50 Treatment of PVR (210)
Subretinal implant of sirolimus and TA Poly butylmethacrylate, poly
ethylene-co-vinyl acetate
Treatment of ocular inflammation (211)
Intravitreal implant of fluocinolone acetonide PVA Controlled release for more than
1 year to treat severe uveitis
(212)
FK506 PGLC Prolongation of corneal allograft
survival
(139)
Cyclosporine A PGLC Treatment of uveitis (138)
Intracameral implant of dexamethasone Corneal graft rejection (213)
Scleral implants of GCV PLA CMV retinitis (137)
Scleral implant of Ethacrynic acid (ECA) PLGA films To reduce IOP for 10 days (214)
Cyclosporin A (Oculex Drug Delivery System) PLGA Prophylaxis and treatment of corneal
transplant rejection in humans
(215)
Dexamethasone PLGA Anterior segment drug delivery system
in patients after phacoemulsification
(216)
Intracapsular ring releasing 5-FU – Preventing posterior capsule opacification
(PCO) in rabbit eyes
(217)
Heparin PLGA Posterior capsular opacification (PCO)
in rabbits
(218)
PVA–EVA Polyvinyl alcohol–ethylene vinyl acetate, PVA polyvinyl alcohol, PGLC ploy glycolide-co-clatide-co-caprolactone polymer, PLGA
poly latide-co-glycolide-acid, PLA poly lactic acid, POE poly ortho esters
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Eligard®, represents a similar technology which is used for
the treatment of prostate cancer. Table III summarizes recent
development in hydrogel based formulations.
IONTOPHORESIS
Ocular iontophoresis has gained significant interest
recently due to its non-invasive nature of delivery to both
anterior and posterior segment. It requires a mild electric
current which is applied to enhance ionized drug penetration
into tissue. This mode of delivery can overcome the potential
side effects associated with intraocular injections and implants
mentioned earlier. OcuPhor™ system has been designed with
an applicator, dispersive electrode and a dose controller for
transscleral iontophoresis (DDT) (152, 153). This device
releases the active drug into retina-choroid as well. A similar
device has been designed called Visulex™ to allow selective
transport of ionized molecules through sclera. Transcorneal
and transscleral iontophoresis have been extensively
employed to deliver a wide variety of drug molecules like
gentamicin and dexamethasone. Delivery of antibiotics by
iontophoresis has resulted in significant fewer bacterial
colonies in cornea compared to the eye drops. Examples of
antibiotics successfully employed are gentamicin, tobramycin
and ciprofloxacin but not vancomycin because of its high
molecular weight (154–156). Successful delivery was obtained
with dexamethasone and with antisense ODNs (157, 158). A
number of antibiotics, including gentamicin, cephazolin,
ticarcilin, amikacin and vancomycin have been successfully
delivered into the vitreous of rabbit eyes. Transscleral
iontophoresis of steroids (dexamethasone and methyl pred-
nisolone), amikacin, gentamicin and other drugs was also
reported (159–164).
MICRONEEDLE
Recently, researchers have attempted microneedle to
deliver drug to posterior segment as an alternative to topical
route. The magnitude of lateral and transverse diffusion of
sulforhodamine was found to be similar across human
cadaver sclera. An evaluation of coated solid metal micro-
needle to deliver the drug was carried out both in-vitro and
in-vivo. Microneedle had shown excellent in vitro penetration
into sclera and rapid dissolution of coating solution after
insertion. In-vivo drug level was found to be significantly
higher than the level observed following topical drug
administration. This mode of drug delivery was also success-
ful in the delivery of pilocarpine (165). The inventors have
claimed to deliver drug successfully across both sclera and
cornea by coated microneedle with minimum invasion.
GENE DELIVERY
Recently, various strategies have been adopted to deliver
nucleic acids to a specific site within the eye. Designing delivery
system for antisense ODNs, aptamers or siRNAs is a challeng-
ing task for researchers in ocular delivery field because of high
molecular weight, size, surface charge, solubility of the active
drug and intrinsic complexities associated with the structure
of ocular tissues like retina and cornea (105).
Table IV summarizes the recent developments happened
in the field targeting various growth factors. Recently, FDA
has approved Vitravene®, an ODNs for the treatment of
CMV in AIDS patients and Macugen® (pegaptanib sodium
injection) which is an aptamer for the treatment of “wet”
AMD (209, 210). Non viral vectors have gained wide
acceptance in gene delivery because of their ability to
overcome disadvantages of viral vectors such as immunoge-
nicity, safety and potential persistence in the brain (166–168).
A major challenge associated with current system is its
inability to achieve higher transfection efficiency. “Naked”
DNA, physical vectorisation of the genetic material and
chemical methods are three main modes of delivery among
nonviral gene therapy. An extensive effort to deliver naked
DNA by topical, intracameral, intracorneal, subconjunctival,
intravitreal and by subretinal routes has been reviewed by
Bloquel et al., (169). The same authors have described
physical methods such as gene gun, electron transfer,
Table III. Recent Developments on the Hydrogel Based Formulations
Drug Polymer Mechanism of gelation Ref
Pefloxacin mesylate Gelrite gellan gum Ion (219)
Gatifloxacin Alginate and HPMC Ion (220)
Indomethacin Gelrite (gellan gum) Ion (221)
Ciprofloxacin HCL Gelrite gellan gum and sodium alginate Ion (222)
Gatifloxacin Ion (223)
Timolol maleate Gellan gum Ion (224)
Ofloxacin Carbopol 940 and HPMC pH (225)
Puerarin Carbopol/HPMC-based gel pH (226)
Puerarin Poloxamer analogs/carbopol pH (227)
Fluconazole In-situ gelling eye drops – (228)
Ganciclovir In-situ gelling eye drops – (229)
Timolol maleate Pluronic F127 Temperature (148)
Timolol maleate poly(Nisopropylacrylamide)-chitosan Temperature (230)
Pilocarpine Alginate and pluronic-based in situ gelling Ion and temperature (231)
Timolol maleate Pluronic F-127 and chitosan pH and temperature (232)
Gatifloxacin Pluronic F127-g-poly(acrylic acid) copolymers pH and temperature (233)
Pilocarpine Xyloglucan Temperature (150)
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iontophoresis and ultrasound in this review. The authors have
also focused on chemical methods such as liposomes, poly-
plexes, and PEGylated RNA aptamers.
CONCLUSIONS
Effective treatment of ocular diseases is a formidable
challenge for scientists in the field especially because of the
nature of diseases and presence of the ocular barriers
especially in posterior ocular segments. An ideal therapy
should maintain effective levels of drug for the longer
duration following a single application. Drug delivery by
topical and intravitreal routes cannot be considered safe,
effective and patient friendly. Drug delivery by periocular
route can potentially overcome many of these limitations and
also can provide sustained drug levels in ocular pathologies
affecting both segments. Transporter targeted delivery can be
a promising strategy for many drug molecules. Colloidal
carriers can substantially improve the current therapy and
may emerge as an alternative following their periocular
administration. In recent years, scientists have focused on
designing a strategy with a multidisciplinary approach e.g.
microneedle, iontophoresis and MRI. Continued innovation
in gene delivery appears to be very exciting for a gamut of
diseases. Designing these innovative techniques has given an
unprecedented momentum for their protection by intellectual
rights. In future, much of the emphasis will be given to
achieve non-invasive sustained drug release for eye disorders
in both segments. A clear understanding of the complexities
associated with tissues in normal and pathological conditions,
physiological barriers and multicompartmental pharmacoki-
netics would greatly hasten further development in the field.
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